Nonsteroidal aromatase3
- Postmenopausal women with hormone-receptor positive breast cancer receiving nonsteroidal aromatase inhibitors. (harborcompounding.com)
- 50 postmenopausal women with hormone receptor-positive breast cancer receiving nonsteroidal aromatase inhibitors received a 12-week course of low dose estriol 0.005% In a phase II, randomized, double-blind, placebo-controlled trial for evaluation of vaginal maturation, vaginal pH, and vulvovaginal atrophy. (harborcompounding.com)
- Anastrozole is a nonsteroidal aromatase inhibitor. (empowerpharmacy.com)
Post-menopausal1
- Unlike doctor prescribed topical hormone creams and all the OTC products I tried, Membrasin cream has been the first and only product that has helped with my post-menopausal atrophic vaginitis, without side effects or making the problem worse. (membrasinlife.com)
Vaginal atrophy3
- Low doses of Estriol have also been clinically shown to be effective in treatment of postmenopausal women suffering from vaginal atrophy undergoing aromatase inhibitor treatment. (harborcompounding.com)
- Recent trials indicate benefits for vaginal atrophy in hormone receptor positive breast cancer undergoing aromatase inhibitor therapy. (harborcompounding.com)
- these physical changes have been referred to as vulvovaginal atrophy (VVA), vaginal atrophy, and atrophic vaginitis. (obgynkey.com)
Vulva1
- atrophic vaginitis - thinning of the membranes of the vulva , the vagina , the cervix , and the outer urinary tract , along with considerable shrinking and loss in elasticity of all of the outer and inner genital areas. (mdwiki.org)
Postmenopausal women3
- Aromatase inhibitors are considered to be a standard of therapy and drug class of choice for the treatment of early breast cancer in postmenopausal women with hormone-receptor positive disease. (empowerpharmacy.com)
- The American Society of Clinical Oncology recommends that all postmenopausal women with hormone receptor-positive early breast cancer receive adjuvant aromatase inhibitor therapy. (empowerpharmacy.com)
- In postmenopausal women, the principal source of circulating estrogens is from the conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by aromatase in peripheral tissues. (empowerpharmacy.com)
Hormone1
- menopausal hormone therapy (MHT), clonidine , gabapentin , or selective serotonin reuptake inhibitors . (mdwiki.org)
Include1
- Options include 5 years of an aromatase inhibitor or sequential therapy with 2-3 years or 5 years of tamoxifen followed by 2-3 years or 5 years of an aromatase inhibitor. (empowerpharmacy.com)
Estrogen2
- Men sometimes wish to lower estrogen via aromatase inhibition. (harddiskinformatica.com)
- Hakimi S, Delazar A, Mobaraki-Asl N, Amiri P, Tavassoli H, Safari M. Comparison of the effects of fenugreek vaginal cream and ultra low-dose estrogen on atrophic vaginitis. (harddiskinformatica.com)
Increase1
- Coadministration with CYP3A4 inhibitors may increase plasma concentrations of estrogens and toxicities. (medscape.com)